AQUESTIVE THERAPEUTICS INC (AQST) competitors & alternatives
Health Care · NASDAQ
AQUESTIVE THERAPEUTICS INC (AQST)'s top competitors and alternatives — its most similar public companies — include ZEVRA THERAPEUTICS INC (ZVRA), Jazz Pharmaceuticals (JAZZ), ORAMED PHARMACEUTICALS INC (ORMP), Alnylam Pharmaceuticals (ALNY), SPRUCE BIOSCIENCES INC (SPRB), OMEROS CORP (OMER), GALECTIN THERAPEUTICS INC (GALT), SOLID BIOSCIENCES INC (SLDB), AN2 THERAPEUTICS INC (ANTX), SAVARA INC (SVRA), XERIS BIOPHARMA HOLDINGS INC (XERS) and HARMONY BIOSCIENCES HLDG INC (HRMY). These are AQUESTIVE THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AQST competitors & alternatives
-
ZEVRA THERAPEUTICS INCZVRAHealth Care
Zevra brings life-changing therapies to ultra-rare neurodegenerative and metabolic diseases, with FDA-approved MIPLYFFA for Niemann-Pick disease type C now…
$12.14 (as of 2026-07-22) · market cap $762M
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
ORAMED PHARMACEUTICALS INCORMPHealth Care
Oramed is a clinical-stage pharmaceutical company developing oral insulin delivery technology while actively investing in healthcare companies to diversify…
$4.02 (as of 2026-07-22) · market cap $165M
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
OMEROS CORPOMERHealth Care
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem…
$9.84 (as of 2026-07-22) · market cap $703M
-
GALECTIN THERAPEUTICS INCGALTHealth Care
Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer.
$3.50 (as of 2026-07-22) · market cap $253M
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
AN2 THERAPEUTICS INCANTXHealth Care
AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other…
$4.89 (as of 2026-07-22) · market cap $176M
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
Not quite? Describe exactly what you want →
Peers are AQUESTIVE THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AQUESTIVE THERAPEUTICS INC (AQST).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.